What a test can show
Clinical sequencing and deletion/duplication analysis interpreted with IHC/MSI and family history.
Monogenic conditions
MSH6Lynch syndrome
Pathogenic germline variants raise Lynch-associated cancer risks, with a spectrum and age profile distinct from MLH1/MSH2.
RELATIONSHIP VALIDITYHigh: established causality
ACTIONABILITYHigh after confirmation
SOURCE CHECKLinks and claim boundaries are editorially checked; external expert review is stated only with named disclosure
Practical meaning
One Lynch-syndrome risk schedule cannot be applied to every gene.
Where knowledge ends
Normal IHC does not exclude every pathogenic variant; a VUS does not confirm the syndrome.
SOURCES AND VERSION
Verifiable, not ‘trust us’.
Updated: 14 August 2026. Any clinical interpretation requires the exact variant, testing method, family information and medical context.